BriaCell Therapeutics Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCTX research report →
Price Chart
About the company
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab.
- CEO
- William V. Williams
- IPO
- 2012
- Employees
- 31
- HQ
- West Vancouver, BC, CA
Get TickerSpark's AI analysis on BCTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $26.72M
- P/E
- -0.33
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.63
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -170.70%
- ROIC
- -230.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-36,054,237
- Net Income
- $-34,904,262-32.7%
- EPS
- $-6.97+88.9%
- OCF Growth
- -1.7%
- FCF Growth
- -2.2%
- 52W High
- $13.09
- 52W Low
- $2.60
- 50D MA
- $3.68
- 200D MA
- $3.74
- Beta
- 1.52
- RSI (14)
- 39
- Avg Volume
- 250.81K
No earnings-call transcripts are available for BCTX yet.
- Free Float
- 98.6%
- Shares Outstanding
- 8.73M
- Float Shares
- 8.61M
of shares held by institutions
19 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cable Car Capital, LP | 216.82K | 0 |
| Hrt Financial LP | 35.25K | ▲ 344 |
| Jane Street Group, LLC | 21.73K | ▼ 4.78K |
| Citadel Advisors LLC | 10.43K | ▲ 10.43K |
| National Bank Of Canada | 2.17K | ▲ 369 |
| Federation Des Caisses Desjardins Du Quebec | 450 | 0 |
| Morgan Stanley | 420 | ▼ 613 |
| Ubs Group AG | 373 | ▼ 43.27K |
| Allworth Financial LP | 100 | 0 |
| Ssa Swiss Advisors AG | 37 | 0 |
| Provenance Wealth Advisors, LLC | 34 | ▲ 34 |
| Group One Trading LLC | 16 | 0 |
Held by 1 ETFs
Biggest fund positions in BCTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 24 | Lustig Marc | buy | 902,935 |
| May 14, 24 | Lustig Marc | buy | 902,935 |
| Dec 28, 22 | Bondarenko Jamieson | buy | 28,000 |
| Dec 23, 22 | Williams William V. | buy | 2,530 |
| Dec 20, 22 | Bondarenko Jamieson | buy | 22,000 |
| Aug 1, 22 | Bondarenko Jamieson | other | 0 |
| Mar 29, 21 | Bondarenko Jamieson | other | 0 |
| Aug 1, 22 | Bondarenko Jamieson | other | 0 |
| Aug 12, 21 | Bondarenko Jamieson | other | 0 |
| Jul 8, 21 | Bondarenko Jamieson | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BCTX coverage
Recent articles, reports, and earnings notes.
No research on BCTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BCTX report →Briacell Therap (NASDAQ:BCTX) Shares Break Above 200 Day Moving Average – Should You Sell?
defenseworld.net · Nov 7
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
globenewswire.com · Nov 6
BriaCell Awarded 2026 “Immunotherapy Solution of the Year” By BioTech Breakthrough
globenewswire.com · Nov 5
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
globenewswire.com · Nov 3
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
globenewswire.com · Oct 23
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
globenewswire.com · Oct 6
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study
globenewswire.com · Sep 14
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
globenewswire.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.